Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 1;140(10):982-993.
doi: 10.1001/jamaophthalmol.2022.3628.

Ophthalmological Findings in Youths With a Newly Diagnosed Brain Tumor

Affiliations

Ophthalmological Findings in Youths With a Newly Diagnosed Brain Tumor

Myrthe A Nuijts et al. JAMA Ophthalmol. .

Abstract

Importance: Visual impairment is an irreversible adverse effect in individuals who experienced a childhood brain tumor. Ophthalmological evaluation at diagnosis enables early detection of vision loss, decision-making about treatment, and when applicable, the timely use of visual interventions. However, awareness of visual impairment in clinical practice is suboptimal, and adherence to ophthalmological evaluation needs to be improved.

Objective: To assess the prevalence and types of abnormal ophthalmological findings in youths with a newly diagnosed brain tumor.

Design, setting, and participants: In this nationwide, prospective cohort study, youths aged 0 to 18 years with a newly diagnosed brain tumor between May 15, 2019, and August 11, 2021, were consecutively enrolled in 4 hospitals in the Netherlands, including the dedicated tertiary referral center for pediatric oncology care.

Exposures: A standardized and comprehensive ophthalmological examination, including orthoptic evaluation, visual acuity testing, visual field examination, and ophthalmoscopy, was performed within 4 weeks from brain tumor diagnosis.

Main outcomes and measures: The main outcomes were prevalence and types of visual symptoms and abnormal ophthalmological findings at brain tumor diagnosis.

Results: Of 170 youths included in the study (96 [56.5%] male; median age, 8.3 years [range, 0.2-17.8 years]), 82 (48.2%) had infratentorial tumors; 53 (31.2%), supratentorial midline tumors; and 35 (20.6%), cerebral hemisphere tumors. A total of 161 patients (94.7%) underwent orthoptic evaluation (67 [41.6%] preoperatively; 94 [58.4%] postoperatively); 152 (89.4%), visual acuity testing (63 [41.4%] preoperatively; 89 [58.6%] postoperatively); 121 (71.2%), visual field examination (49 [40.4%] preoperatively; 72 [59.6%] postoperatively); and 164 (96.5%), ophthalmoscopy (82 [50.0%] preoperatively; 82 [50.0%] postoperatively). Overall, 101 youths (59.4%) presented with visual symptoms at diagnosis. Abnormal findings were found in 134 patients (78.8%) during ophthalmological examination. The most common abnormal findings were papilledema in 86 of 164 patients (52.4%) who underwent ophthalmoscopy, gaze deficits in 54 of 161 (33.5%) who underwent orthoptic evaluation, visual field defects in 32 of 114 (28.1%) with reliable visual field examination, nystagmus in 40 (24.8%) and strabismus in 32 (19.9%) of 161 who underwent orthoptic evaluation, and decreased visual acuity in 13 of 152 (8.6%) with reliable visual acuity testing. Forty-five of 69 youths (65.2%) without visual symptoms at diagnosis had ophthalmological abnormalities on examination.

Conclusions and relevance: The results of this study suggest that there is a high prevalence of abnormal ophthalmological findings in youths at brain tumor diagnosis regardless of the presence of visual symptoms. These findings support the need of standardized ophthalmological examination and the awareness of ophthalmologists and referring oncologists, neurologists, and neurosurgeons for ophthalmological abnormalities in this patient group.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure.
Figure.. Patient Flowchart
Patients were aged 0 to 18 years. AUMC indicates Amsterdam University Medical Center; EMC, Erasmus Medical Center; PMC, Princess Máxima Center for Pediatric Oncology; UMCU, University Medical Center Utrecht.

Comment in

References

    1. Howlader N, Noone AM, Krapcho M, et al. . SEER cancer statistics review, 1975-2018. National Cancer Institute. 2021. Accessed January 13, 2022.https://seer.cancer.gov/csr/1975_2018/
    1. Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro Oncol. 2020;22(12)(suppl 2):iv1-iv96. doi:10.1093/neuonc/noaa200 - DOI - PMC - PubMed
    1. Armstrong GT, Liu Q, Yasui Y, et al. . Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009;101(13):946-958. doi:10.1093/jnci/djp148 - DOI - PMC - PubMed
    1. Pillai S, Metrie M, Dunham C, Sargent M, Hukin J, Steinbok P. Intracranial tumors in infants: long-term functional outcome, survival, and its predictors. Childs Nerv Syst. 2012;28(4):547-555. doi:10.1007/s00381-012-1707-y - DOI - PubMed
    1. Saha A, Salley CG, Saigal P, et al. . Late effects in survivors of childhood CNS tumors treated on Head Start I and II protocols. Pediatr Blood Cancer. 2014;61(9):1644-1652. doi:10.1002/pbc.25064 - DOI - PMC - PubMed

Publication types